Document Detail


Peptide YY: a potential therapy for obesity.
MedLine Citation:
PMID:  15777187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity now represents a modern epidemic in western society with major health and economic consequences. Unfortunately, previous pharmacological approaches to the treatment of obesity have been associated with life-threatening side effects and limited efficacy. Over recent years there has been a marked increase in our understanding of the physiological mechanisms that regulate body weight and how these are perturbed in obesity. One therapeutic strategy is to develop drugs which both mimic and enhance the body's own satiety signals. The gut hormone peptide tyrosine tyrosine (PYY), which is released postprandially from the gastrointestinal tract, has recently been shown to be a physiological regulator of food intake. Peripheral administration of PYY reduces feeding in rodents via a mechanism which requires the Y2 receptor and is thought to primarily involve modulation of the hypothalamic arcuate nucleus (ARC) circuitry. In humans a single 90-minute infusion of PYY has been shown to markedly reduce subsequent 24-hour caloric intake in lean, normal-weight and obese subjects. Moreover, obese subjects have been found to have low levels of fasting and postprandial PYY suggesting a role for this hormone in the pathogenesis of obesity. Although studies examining the effects of chronic peripheral administration of PYY to humans are awaited, the results from continuous infusion studies in a number of obese rodent models are encouraging with reductions in food intake, body weight and adiposity observed. Potential therapeutic manipulations based on the PYY system include development of Y2 agonists, exogenously administration of PYY or increased endogenous release from the gastrointestinal tract.
Authors:
D Renshaw; R L Batterham
Related Documents :
22444297 - 'mealthy' food: meat as a healthy and valuable source of micronutrients.
6880927 - Delay of gratification in obese children.
10535677 - Lateral hypothalamic serotonergic responsiveness to food intake in rat obesity as measu...
19616997 - Frontal attentional responses to food size are abnormal in obese subjects: an electroen...
22280227 - Dietary iodine and thyroid cancer risk in french polynesia: a case-control study.
2211487 - In vitro assay for protein digestibility: interlaboratory study.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets     Volume:  6     ISSN:  1389-4501     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-21     Completed Date:  2005-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  171-9     Citation Subset:  IM    
Affiliation:
Centre for Diabetes and Endocrinology, University College London, Rayne Institute, 5 University Street, London WC1E 6JJ, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Sequence
Animals
Appetite / drug effects
Eating / drug effects
Humans
Molecular Sequence Data
Obesity / drug therapy*
Peptide YY / chemistry,  therapeutic use*
Receptors, Gastrointestinal Hormone / chemistry,  metabolism
Stomach / surgery
Chemical
Reg. No./Substance:
0/Receptors, Gastrointestinal Hormone; 0/peptide YY receptor; 106388-42-5/Peptide YY

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ghrelin and energy balance: focus on current controversies.
Next Document:  Pancreatic amylin as a centrally acting satiating hormone.